|
Florian Schönharting is a co-founder and partner of Nordic Biotech. Mr. Schönharting is a pioneer in biotechnology investments and has more than 13 years of investment experience in the biotechnology and healthcare industry.
Mr. Schönharting\'s experience comes primarily from a 10-year tenure at Bank Invest Asset Management, a Danish private & public equity group, most recently as managing director, in charge of biotech investments. During his tenure, Mr. Schönharting executed some 20 investments, including Biomarin, Genmab, Profound Pharma (Maxygen Inc.), Bavarian Nordic, Pharmexa, Pyrosequencing and Glyko Biomedical. Mr. Schönharting earned a master\'s degree in business economics (finance) from the Copenhagen Business School, and was given the McKinsey & Co award for best-of-year student. Florian Schönharting is currently a member of the Board of Directors of the Danish Venture Capital Association (DVCA) and the Danish Corporate Governance Association (DCGA). | 